OROS Hydromorphone Development Unaffected By Palladone Withdrawal, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson says that the withdrawal of Purdue Pharma's Palladone (hydromorphone extended release) will not affect development of its OROS hydromorphone opioid analgesic
You may also be interested in...
J&J’s OROS Hydromorphone Requires Additional Trial
Following meetings with FDA, the company will modify the development program for the chronic pain agent.
J&J’s OROS Hydromorphone Requires Additional Trial
Following meetings with FDA, the company will modify the development program for the chronic pain agent.
J&J Defends Duragesic, Ortho Evra Patches
Safety of transdermal delivery system is not undermined by recent reports of adverse events with the products, the firm says. Mylan defends its own transdermal fetanyl patch, stating that FDA safety review pertains to Duragesic.